Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

Find the latest Viking Therapeutics, Inc. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing.

Jan 8, 2025 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today...

Feb 27, 2024 · Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo. Up to 13.1% Placebo-Adjusted Mean Weight Loss (14.7% From Baseline) Observed After 13 Weeks of Treatment; No Plateau Observed.

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials.

Jan 21, 2025 · Viking Therapeutics Inc.’s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company’s promising obesity-drug program and its potential appeal to a deep-pocketed ...

Jan 6, 2025 · Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...

Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

Jan 21, 2025 · Viking Therapeutics Inc.'s stock jumped 3% Tuesday, after a bullish note from Oppenheimer highlighted the company's promising obesity-drug program and its potential appeal to a deep-pocketed partner.

Dec 3, 2024 · Viking Therapeutics is a promising GLP-1 drugmaker which has more than doubled in value this year. Recently, the stock has come under pressure, potentially due to the recent election...